DrugPatentWatch Database Preview
PHEXXI Drug Profile
» See Plans and Pricing
Which patents cover Phexxi, and when can generic versions of Phexxi launch?
Phexxi is a drug marketed by Evofem Inc and is included in one NDA.
The generic ingredient in PHEXXI is citric acid; lactic acid; potassium bitartrate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the citric acid; lactic acid; potassium bitartrate profile page.
Summary for PHEXXI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | PHEXXI at DailyMed |
Generic Entry Opportunity Date for PHEXXI
Generic Entry Date for PHEXXI*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
GEL;VAGINAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for PHEXXI
| Drug Class | Calculi Dissolution Agent Anti-coagulant |
| Mechanism of Action | Acidifying Activity Calcium Chelating Activity |
| Physiological Effect | Decreased Coagulation Factor Activity |
US Patents and Regulatory Information for PHEXXI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evofem Inc | PHEXXI | citric acid; lactic acid; potassium bitartrate | GEL;VAGINAL | 208352-001 | May 22, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
